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hepatitis A and its associated complications. Other details of the model were not given in this study, but readers are referred to Rein et al 2007 for further information.
Sources searched to identify primary studies
Little information on the sources of the clinical data was provided, but readers are referred to Rein et al 2007 for this information. Most of the clinical data came from the National Notifiable Disease Surveillance System.
Methods used to judge relevance and validity, and for extracting data
No details of the approach used to identify the published studies were given but further detail will be found in Rein et al 2007. The algorithm used to estimate the proportion of infections prevented by herd immunity was reported in detail and a justification was given.
Measure of benefits used in the economic analysis
The summary benefit measures used were the life-years (LYs) and quality-adjusted life-years (QALYs). These were estimated using the decision model. No information on the sources of utility weights used to derive the QALYs was provided. The benefits were discounted at an annual rate of 3%.
Direct costs
The analysis was carried out from a societal perspective. It included the direct costs associated with vaccination and treatment of the disease. A breakdown of the cost items was not provided. The unit costs and the resource quantities were not presented separately. The costs and quantities were derived from the published decision model. The costs were incurred over a long time period and an annual discount rate of 3% was used. The price year was 2005.
Statistical analysis of costs
The costs appear to have been treated deterministically.
Indirect Costs
The analysis appropriately considered productivity costs given that a societal perspective was adopted. The three main categories of productivity losses considered were the productivity loss after death from hepatitis A, the productivity loss while ill with hepatitis A, and the productivity loss by parents caring for children with acute hepatitis A. The costs in the cost-utility analysis included all of these costs except productivity loss while ill with hepatitis A, which was taken into account as a component of QALYs. No information on the sources of these costs was provided. As in the analysis of the direct costs, the price year was 2005 and an annual discount rate of 3% was used.
Currency

US dollars ($).
Sensitivity analysis
A univariate sensitivity analysis was performed to assess the robustness of the cost-effectiveness and cost-utility ratios to variations in the herd-immunity parameters, vaccination costs, discount rate, incidence and rate of decline in incidence of hepatitis A, duration of immunity from hepatitis A vaccine, immunisation coverage, and quality of life lost during acute hepatitis A. The sources of the alternative ranges of values were not reported.
Estimated benefits used in the economic analysis
The expected LYs gained with the vaccination strategy over no vaccination were 206 in the direct-effects model and 675 in the full model where the indirect effects of herd immunity were considered (462 out-of-cohort and 7 within-
